Trial Information
A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based Therapy
Inclusion Criteria:
histologically confirmed epithelial ovarian cancer, cancer of the fallopian tube or
peritoneum refractory to platinum- and taxane-based chemotherapy measurable or
non-measurable disease written informed consent aged 18 years or older Karnofsky
performance status > 60%
Exclusion Criteria:
complete bowel obstruction symptomatic brain metastases known hypersensitivity to
evaluated drugs inadequate kidney function inadequate hepatic function evidence of
clinically active interstitial lung disease history of congestive heart failure > NYHA 2
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Safety and tolerability
Principal Investigator
Uwe Wagner, Prof.Dr.
Investigator Role:
Principal Investigator
Investigator Affiliation:
AGO Study Group
Authority:
Germany: Federal Institute for Drugs and Medical Devices
Study ID:
AGO-OVAR 2.6
NCT ID:
NCT00189358
Start Date:
Completion Date:
Related Keywords:
- Ovarian Cancer
- Cancer of the Fallopian Tube
- Peritoneal Cancer
- cancer
- cancer alternative therapies
- ovarian cancer
- tyrosine kinase inhibitor
- Carcinoma
- Ovarian Neoplasms
- Peritoneal Neoplasms
- Fallopian Tube Neoplasms
- Neoplasms, Glandular and Epithelial